Epithelial cell adhesion molecule targeted nutlin-3a loaded immunonanoparticles for cancer therapy

Acta Biomaterialia

Volumn 7, Issue 1, 2011, Pages 355-369

  Das, Manasi ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Nanoparticle; Nutlin 3a; p53 activation; Surface functionalization; Targeted cancer therapy

Indexed keywords

ANTIBODIES; BIOCHEMISTRY; CELL ADHESION; CELL CULTURE; CELL DEATH; CELL MEMBRANES; CONTROLLED DRUG DELIVERY; DISEASES; MITOCHONDRIA; MOLECULES; ONCOLOGY; TARGETED DRUG DELIVERY;

'LACUNA'; ANTICANCER DRUG; CANCER THERAPY; EPITHELIAL CELL ADHESION MOLECULES; NUTLIN-3A; P53 ACTIVATION; P53 FUNCTION; SURFACE FUNCTIONALIZATION; TARGETED CANCER THERAPY; THERAPEUTIC STRATEGY;

NANOPARTICLES;

DRUG CARRIER; EPITHELIAL CELL ADHESION MOLECULE; NANOPARTICLE; NUTLIN 3; P21 ACTIVATED KINASE; POLYGLACTIN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

MURINAE;

EID: 78049435057     PISSN: 17427061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actbio.2010.08.010     Document Type: Article

References (56)

1. K.H. Vousden, and X. Lu Live or let die: the cell's response to p53 Nat Rev Cancer 2 2002 594
2. P. Hainaut, and M. Hollstein P53 and human cancer: the first ten thousand mutations Adv Cancer Res 77 2000 81
3. J. Momand, and G.P. Zambetti Mdm-2: "big brother" of p53 J Cell Biochem 64 1997 343
4. A. Bottger, V. Bottger, C. Garcia-Echeverria, P. Chene, H.K. Hochkeppel, and W. Sampson Molecular characterization of the hdm2-p53 interaction J Mol Biol 269 1997 744
5. K. Ding, Y. Lu, Z. Nikolovska-Coleska, S. Qiu, Y. Ding, and W. Gao Structure-based design of potent non-peptide MDM2 inhibitors J Am Chem Soc 127 2005 10130
6. L.T. Vassilev MDM2 inhibitors for cancer therapy Trends Mol Med 13 2007 23
7. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, and Z. Filipovic In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844
8. M. Michaelis, F. Rothweiler, D. Klassert, A. von Deimling, K. Weber, and B. Fehse Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3 Cancer Res 69 2009 416
9. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur J Pharm Sci 11 2000 265
10. S.K. Sahoo, and V. Labhasetwar Nanotech approaches to drug delivery and imaging Drug Discov Today 8 2003 1112
11. J. Panyam, and V. Labhasetwar Biodegradable nanoparticles for drug and gene delivery to cells and tissue Adv Drug Deliv Rev 55 2003 329
12. M. Das, C. Mohanty, and S.K. Sahoo Ligand-based targeted therapy for cancer tissue Expert Opin Drug Deliv 6 2009 285
13. P. Went, M. Vasei, L. Bubendorf, L. Terracciano, L. Tornillo, and U. Riede Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers Br J Cancer 94 2006 128
14. J. Winkler, P. Martin-Killias, A. Pluckthun, and U. Zangemeister-Wittke EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins Mol Cancer Ther 8 2009 2674
15. G. Spizzo, P. Went, S. Dirnhofer, P. Obrist, H. Moch, and P.A. Baeuerle Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer Gynecol Oncol 103 2006 483
16. M. Munz, C. Kieu, B. Mack, B. Schmitt, R. Zeidler, and O. Gires The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation Oncogene 23 2004 5748
17. C. Guillouf, X. Grana, M. Selvakumaran, A. De Luca, A. Giordano, and B. Hoffman Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest Blood 85 1995 2691
18. S.K. Sahoo, W. Ma, and V. Labhasetwar Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer Int J Cancer 112 2004 335
19. S. Acharya, F. Dilnawaz, and S.K. Sahoo Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy Biomaterials 30 2009 5737
20. J. Panyam, S.K. Sahoo, S. Prabha, T. Bargar, and V. Labhasetwar Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(d, l-lactide-co-glycolide) nanoparticles Int J Pharm 262 2003 1
21. S.K. Sahoo, and V. Labhasetwar Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention Mol Pharm 2 2005 373
22. R. Misra, and S.K. Sahoo Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy Eur J Pharm Sci 39 2010 152
23. K. Maaser, and J. Borlak A genome-wide expression analysis identifies a network of EpCAM-induced cell cycle regulators Br J Cancer 99 2008 1635
24. T. Van Maerken, F. Speleman, J. Vermeulen, I. Lambertz, S. De Clercq, and E. De Smet Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma Cancer Res 66 2006 9646
25. X. Li, L. Ding, Y. Xu, Y. Wang, and Q. Ping Targeted delivery of doxorubicin using stealth liposomes modified with transferrin Int J Pharm 373 2009 116
26. B.S. Kim, C.S. Kim, and K.M. Lee The intracellular uptake ability of chitosan-coated Poly (d, l-lactide-co-glycolide) nanoparticles Arch Pharm Res 31 2008 1050
27. T.K. Jain, J. Richey, M. Strand, D.L. Leslie-Pelecky, C.A. Flask, and V. Labhasetwar Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging Biomaterials 29 2008 4012
28. A. Cossarizza, M. Baccarani-Contri, G. Kalashnikova, and C. Franceschi A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′- tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1) Biochem Biophys Res Commun 197 1993 40
29. P. Kocbek, N. Obermajer, M. Cegnar, J. Kos, and J. Kristl Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody J Control Release 120 2007 18
30. C.L. Tseng, T.W. Wang, G.C. Dong, S. Yueh-Hsiu Wu, T.H. Young, and M.J. Shieh Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting Biomaterials 28 2007 3996
31. R. Misra, S. Acharya, F. Dilnawaz, and S.K. Sahoo Sustained antibacterial activity of doxycycline-loaded poly(d, l-lactide-co-glycolide) and poly(epsilon-caprolactone) nanoparticles Nanomedicine 4 2009 519
32. J. Panyam, and V. Labhasetwar Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles Mol Pharm 1 2004 77
33. M. Miyachi, N. Kakazu, S. Yagyu, Y. Katsumi, S. Tsubai-Shimizu, and K. Kikuchi Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells Clin Cancer Res 15 2009 4077
34. N. Zamzami, P. Marchetti, M. Castedo, C. Zanin, J.L. Vayssiere, and P.X. Petit Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo J Exp Med 181 1995 1661
35. R. Fauvet, C. Dufournet, C. Poncelet, C. Uzan, D. Hugol, and E. Darai Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours J Surg Oncol 92 2005 337
36. L.T. Vassilev p53 activation by small molecules: application in oncology J Med Chem 48 2005 4491
37. T. Thompson, C. Tovar, H. Yang, D. Carvajal, B.T. Vu, and Q. Xu Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis J Biol Chem 279 2004 53015
38. V. Guillemard, and H.U. Saragovi Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity Cancer Res 61 2001 694
39. V.P. Torchilin, A.N. Lukyanov, Z. Gao, and B. Papahadjopoulos-Sternberg Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs Proc Natl Acad Sci USA 100 2003 6039
40. J. You, X. Li, F. Cui, Y. Du, H. Yuan, and F. Hu Folate-conjugated polymer micelles for active targeting to cancer cells: preparation, in vitro evaluation of targeting ability and cytotoxicity Nanotechnology 19 2008 045102
41. H. Jinno, T. Ikeda, A. Matsui, Y. Kitagawa, M. Kitajima, and H. Fujii Sentinel lymph node biopsy in breast cancer using technetium-99m tin colloids of different sizes Biomed Pharmacother 56 Suppl. 1 2002 213s
42. S. Parveen, and S.K. Sahoo Polymeric nanoparticles for cancer therapy J Drug Target 16 2008 108
43. E. Lee, and S.J. Lim The association of increased lung resistance protein expression with acquired etoposide resistance in human H460 lung cancer cell lines Arch Pharm Res 29 2006 1018
44. J. Panyam, W.Z. Zhou, S. Prabha, S.K. Sahoo, and V. Labhasetwar Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery FASEB J 16 2002 1217
45. Y. Mo, and L.Y. Lim Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin J Control Release 108 2005 244
46. J.S. Park, T.H. Han, K.Y. Lee, S.S. Han, J.J. Hwang, and D.H. Moon N-Acetyl histidine-conjugated glycol chitosan self-assembled nanoparticles for intracytoplasmic delivery of drugs: endocytosis, exocytosis and drug release J Control Release 115 2006 37
47. M.K. Reddy, J.K. Vasir, S.K. Sahoo, T.K. Jain, M.M. Yallapu, and V. Labhasetwar Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured Circ Cardiovasc Intervent 1 2008 209 216
48. J.W. Harper, G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases Cell 75 1993 805
49. J.T. Zilfou, and S.W. Lowe Tumor suppressive functions of p53 Cold Spring Harb Perspect Biol 1 2009 a001883
50. H. Hermeking, C. Lengauer, K. Polyak, T.C. He, L. Zhang, and S. Thiagalingam 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression Mol Cell 1 1997 3
51. J.J. Lemasters, A.L. Nieminen, T. Qian, L.C. Trost, S.P. Elmore, and Y. Nishimura The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy Biochim Biophys Acta 1366 1998 177
52. T. Miyashita, and J.C. Reed Tumor suppressor p53 is a direct transcriptional activator of the human bax gene Cell 80 1995 293
53. K. Nakano, and K.H. Vousden PUMA, a novel proapoptotic gene, is induced by p53 Mol Cell 7 2001 683
54. E. Oda, R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, and T. Yamashita Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis Science 288 2000 1053
55. C. Tovar, J. Rosinski, Z. Filipovic, B. Higgins, K. Kolinsky, and H. Hilton Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy Proc Natl Acad Sci USA 103 2006 1888
56. B. Hoffman, and D.A. Liebermann Apoptotic signaling by c-MYC Oncogene 27 2008 6462